CluenexUnited Therapeutics UTHR
United Therapeutics scores excellent on business quality (8.8 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What United Therapeutics does
United Therapeutics develops life-extending therapies for pulmonary hypertension and organ manufacturing, selling specialized drugs to healthcare providers and hospitals. The business is expanding commercialized PAH treatments while advancing xenotransplantation pipelines visible in recent trials.
- What it does best
United Therapeutics dominates commercializing complex cardiovascular therapies, posting an 86.1% gross margin that outpaces peers like Biogen at 74.0%. This margin power stems from specialized delivery systems and orphan drug exclusivity that protect pricing.
- The main risk
Patent challenges and rival litigation threaten core pulmonary hypertension revenues. A recent patent court loss for a key competitor highlights the aggressive legal environment surrounding its main drug franchise.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin sits at an elite 44.5% alongside a 34.5% free cash flow margin, driving sector-leading returns on equity of 20.2%. The business model scales efficiently as volume increases.
Proprietary drug delivery tech and orphan drug status lock in a specialized base of prescribing physicians. Its operating margin ranks in the 98th percentile of the healthcare sector, showing structural pricing power.
Revenue grew 10.6% over the latest period, showing steady expansion from its core PAH portfolio. Annual figures reveal consistent scaling from $1.5B in 2020 to over $3.1B recently.
With zero debt and $2.9B in cash, the balance sheet is pristine. Free cash flow reached $1.1B, leaving debt costs as a non-factor and providing massive funding capacity for internal R&D.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
1 sold $115K outside pre-planned sales.
Our sealed record on UTHR
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
United Therapeutics scores excellent on the Cluenex quality check (8.8 of 10), measured against its own industry. Profitability is strong, moat strong, growth fast and financial health strong.
In the last 90 days of SEC Form 4 filings: 1 sold $115K outside pre-planned sales.
Nov 4, 2026, before the open.
See UTHR today
- Today's verdict on UTHR, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “United Therapeutics (UTHR)”, https://cluenex.com/stocks/uthr/, data as of Oct 10, 2026.